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Lesions involving the osteochondral unit are difficult to treat. Biomimetic
scaffolds are previously shown as promising alternative. Such devices often
lack multiple functional layers that mimic bone, cartilage, and the interface. In
this study, multilayered scaffolds are developed based on the use of natural
extracellular matrix (ECM)-like biopolymers. Particular attention is paid to
obtain a complex matrix that mimics the native osteochondral transition.
Porous, sponge-like chitosan-collagen-octacalcium phosphate (OCP) scaffolds
are obtained. Collagen content increases while the amount of OCP particles
decreases toward the cartilage layer. The scaffolds are bioactive as a mineral
layer is deposited containing hydroxyapatite at the bony side. The scaffolds
stimulate proliferation of human adipose-derived mesenchymal stem cells,
but the degree of proliferation depends on the cell seeding density. The
scaffolds give rise to a zone-specific gene expression. RUNX2, COL1A1,
BGLAP, and SPP1 are upregulated in the bony layer of the scaffold. SOX9 is
upregulated concomitant with COL2A1 expression in the cartilage zone.
Mineralization in presence of the cells is prominent in the bone area with Ca
and P steadily increasing over time. These results are encouraging for the
fabrication of biomimetic scaffolds using ECM-like materials and featuring
gradients that mimic native tissues and their interface.
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1. Introduction
Osteochondral defects may result from pri-
mary osteoarthritis (OA) or as a conse-
quence of fractures with joint involvement.
Studies on incidence revealed that 10–
15% of persons aged over 60 years suffer
from clinical OA,[1] with an increasing in-
cidence due to obesity and lack of physical
activity.[1–2] Patients with osteochondral le-
sions suffer from pain and loss of function
that may result in disability. Current clin-
ical approaches to heal osteochondral de-
fects remain highly challenging. Moreover,
healing mostly occurs unsatisfactorily. Ad-
vanced OA therapy often results in joint
replacement with known associated risks
and side effects.[3] Other treatments, like
microfracture and matrix-associated autol-
ogous chondrocytes transplantation, still
produce unsatisfactory results in long-term
cartilage regeneration.[4]
Scaffold-based regeneration models have
been reported as a highly promising ap-
proach for osteochondral lesions.[5] Indeed,
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this type of approach may be particularly useful for the regener-
ation of two distinct tissues and a stable interface.[6] The clini-
cal application of such therapeutic scaffolds may be achieved in
a one-step procedure with clear advantages. Ideally, these scaf-
folding materials should be able to promote attachment of the
cells, mimic the natural environment, and integrate into the
surrounding tissue. In addition, cell differentiation should be
supported. This is crucial to promote tissue regeneration.[5b,7]
Scaffolds for osteochondral regeneration should feature mul-
tiple layers to mimic bone, cartilage, and their interface.
Several strategies have been reported to develop scaffolds for os-
teochondral regeneration that can be summarized as i) two sin-
gle scaffolds combined at the defect site, ii) scaffold for bone
and scaffold-free approach for the cartilage layer, iii) single, ho-
mogeneous scaffold for both tissues and the interface, and iv)
single, heterogeneous composite scaffold (elegantly reviewed in
Nooeaid et al.[5b]). As materials of choice, several natural- and
synthetic-origin polymers are being investigated. Examples of
natural materials include collagen, hyaluronan, and chitosan.[8]
Bioactive ceramics, including hydroxyapatite (HA) and calcium
phosphates, are mostly used for the bony layer. These ceramics
are frequently entrapped in a matrix of synthetic polymers widely
used for bone engineering, including polycaprolactone and
poly(lactic acid).[9]
In our study, we developed a chitosan-collagen composite scaf-
fold that contains octacalcium phosphate (OCP) at the top of the
bony layer. The aim was to develop a novel multilayered scaffold
for osteochondral regeneration based on natural extracellular
matrix (ECM)-like materials. Gradients of chitosan and collagen
were used that mimic the distinct tissues and the interface. Such
a material gradient may promote desired stem cell differentiation
that is specific for each tissue zone. In addition, a mineral com-
ponent was incorporated in the bony layer. The scaffolds were
designed as a continuous, single but heterogeneous material to
avoid a predetermined breaking point between the bone and the
cartilage layers. Chitosan and collagen were selected as biopoly-
mers to generate the composite used in the present study.
Chitosan is a natural, non-toxic biopolymer, which is highly
biocompatible, biodegradable, and bioactive. It is structurally
similar to glycosaminoglycan and offers an appropriate stimulus
for stem cell differentiation.[10] Collagen is the main ECM com-
ponent in both native cartilage and bone tissue.[11] The bony layer
in our scaffold includes OCP as the mineral component. Calcium
phosphates are widely used in bone tissue engineering and have
been reported to promote bone regeneration.[12] The developed
scaffolds were carefully characterized for their morphology,
porosity, and pore size as well as their composition, crystallinity,
and mechanical properties. The bioactivity of the scaffolds was
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evaluated in simulated body fluid (SBF) and their biocompat-
ibility with human adipose-derived mesenchymal stem cells
(hAMSCs). Considerable effort was made in evaluating the
differentiation of hAMSCs on each of the different layers of the
scaffold.
Our hypothesis is that by using a single composite scaffold that
contains gradients of natural ECM-like materials and adequate





OCP was synthesized by dripping a solution of 0.04 mol L−1 cal-
cium acetate (Ca(CH3COO)2, VWR BDH Chemicals Ltd., Rad-
nor, PA, USA) into a solution of 0.04 mol L−1 sodium acid
phosphate (Na2HPO4, Panreac Quimica SA, Barcelona, Spain)
and following a reported methodology.[13] The synthesis was per-
formed at 60 °C for 3 h. During precipitation of the OCP, the
solution was maintained under stirring. Subsequently, the pre-
cipitate was filtered and washed several times with distilled water.
Finally, the product obtained was dried at room temperature. Chi-
tosan from shrimp shells, ≈75% deacetylated was obtained from
Sigma Aldrich (St. Louis, MO, USA). Fibers of collagen type I
were used as collagen source (bovine origin, commercial grade,
Novaprom, Lins, Brazil). Both biopolymers were used as received
by the manufacturers. Solutions of chitosan and collagen were
prepared at a concentration of 2%, with constant stirring main-
tained for 24 h. Subsequently, 1% acetic acid was added and the
stirring was continued for another 24 h. All raw materials used
in the study were characterized by FTIR following the procedure
described earlier in Section 2.2.3.
2.1.2. Production of Graded, Composite Multilayered Scaffold
Figure 1 presents a scheme illustrating the sequential layer-by-
layer fabrication methodology to produce the scaffolds. First, the
solutions corresponding to the different layers were indepen-
dently produced (Figure 1A). For the bony layer and the interface,
chitosan-collagen (1:1) was used. Two percent OCP was addition-
ally added to the solution for the bony layer. For the cartilage layer,
the collagen content was increased to obtain a ratio of chitosan-
collagen of 1:3. Under stirring, 1 m NaOH was added to each
layer to neutralize the acetic acid. For the fabrication of the mul-
tilayer composite scaffolds, each solution was stirred to obtain a
foam and poured into a mold followed by a freezing step. Follow-
ing freezing of the first layer, the polymeric solution correspond-
ing to the next layer was deposited on top and the next freezing
cycle was performed. All freezing cycles were performed at
−20 °C. Subsequently, molds containing the three layers were
frozen and lyophilized (Figure 1B). Finally, the scaffolds were cut
out into cylinders of 5 mm diameter using a biopsy punch (Figure
S2, Supporting Information) and sterilized using ethylene oxide
(inpac Medizintechnik GmbH, Birkenfeld, Germany).
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Figure 1. Schematic representation of the fabrication strategy followed to produce the multiphasic chitosan-collagen-octacalcium phosphate scaffolds.
A) Material combinations used to obtain each independent layer. Consecutive freezing of the layers was performed; starting with the bony layer (1), then
the interface (2), and finally the cartilage zone (3). B) Lyophilization of the material composite solutions previously deposited and frozen layer by layer
into a mold. Illustration of the resulting scaffold. Different zones and material composition are identified.
2.2. Scaffold characterization
2.2.1. Morphology and Elemental Composition: Light Microscopy
and Scanning Electron Microscopy—Energy Dispersive Spectroscopy
The structure and morphology (i.e., general and of the sur-
face) of the composite scaffolds were characterized by observa-
tional light microscopy (VHX-900F, Keyence, Osaka, Japan) and
SEM (JSM-6010LV, JEOL, Tokyo, Japan). By means of light mi-
croscopy, image depth of field and surface topography analy-
sis were performed. For this analysis, scaffolds were bisected
to obtain a plane surface. SEM was performed to analyze gen-
eral morphological properties. In addition, an initial insight on
porosity and pores shapes was obtained by this technique. To
detect the presence of elements (i.e., Ca, P, C, and O) of dif-
ferent regions of interest (ROI) on the scaffolds, EDS (INCAx-
Act, PentaFET Precision, Oxford Instruments, Abingdon, UK)
was performed. In addition, an element mapping of the entire
scaffold was also obtained by EDS. Prior to SEM observation, the
scaffolds were coated with platinum by ion sputtering. Backscat-
tered electron imaging was used for overview images and sec-
ondary electron imaging for all detailed images (i.e., higher
magnifications). For EDS analysis, scaffolds were used without
coating.
2.2.2. Pore Size and Wall Thickness Analysis: Micro-Computed
Tomography
Scaffolds were characterized using µCT (SkyScan 1176, Bruker,
Kontich, Belgium) for porosity, pore size, and wall thickness dis-
tribution. N = 4 scaffolds were used for the analysis. Briefly, scaf-
folds were stained with iodine vapor for 12 h and scanned at
40 kV and 600 µA with 9 µm resolution. The tomography was
reconstructed using NRecon software (Version 1.6.9.18, Bruker).
For the characterization of scaffold properties, three ROI repre-
senting the cartilage (ROI 1), interface (ROI 2), and bone (ROI
3) regions were selected and analyzed using CTAnalyser software
(Version 1.17.7.2, Bruker) with adaptive thresholding between 40
and 200 (greyscale) for the collagen structure and global thresh-
olding between 220 and 255 (greyscale) for the OCP particles.
Finally, volume rendering of the scaffold was performed using
CTVoxel (Version 3.3, Bruker).
2.2.3. Chemical and Crystallographic Properties: FTIR and X-Ray
Diffraction
FTIR (IR Prestige-21 spectrometer Shimadzu, Kyoto, Japan) with
attenuated total reflectance was used to analyze the chemical
Adv. Healthcare Mater. 2021, 2001692 2001692 (3 of 18) © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
structure of the raw materials and scaffolds. The spectra were
received in a transmittance mode of over 100 scans in a spectral
range of 400–4000 cm−1. For each raw material, a standard sam-
ple preparation was followed. For each scaffold, the bone and car-
tilage layers were independently analyzed. The crystalline phases
on the scaffolds were detected using thin-film XRD (D8 Advance,
Bruker, XRD Division, Karlsruhe, Germany). The data collection
was performed by the 2𝜃 scan method, with 1° as the incident
beam angle using a Cu K𝛼 X-ray line and a scan speed of 0.05°
min−1 over 9 h.
2.2.4. Mechanical Properties: Oscillatory Shear Measurements
Rheological measurements were performed using an AR-2000ex
rheometer (TA Instruments, New Castle, DE, USA) with the sam-
ples immersed in distilled water. In brief, swollen samples were
placed between parallel plates (non-porous, stainless steel, diam-
eter 12 mm) and the gap was adjusted using a normal force of
0.2 N. Once the samples reached an equilibrium stage, a gap was
adjusted to 1000 µm. The specimen temperature was set at 37 °C
and controlled by a Peltier heating stage. Initial measurements
were performed in a shear deformation mode. To start, a range
of strain amplitudes was determined in which the samples ex-
hibited a linear viscoelasticity. Dynamic strain/frequency sweep
tests were performed. For the strain test, amplitudes from 0.1%
to 20% at a frequency of 1 Hz were used. Thereby, the dynamic
shear modulus was determined as function of strain. For the fre-
quency test, frequencies in the range 0.01–70 Hz were used. The
strain corresponding to the sample linear region was used as a
fixed value. Here, the dependency of the dynamic shear modulus
and loss factor on frequency was obtained. Values of the G′, G″,
G*, and tan 𝛿 were obtained. Standard equations reported else-
where were used for G* (
√
(G′)2 + (G′′)2) and tan 𝛿 (G′′/G′).[14]
2.3. Scaffold Bioactivity in Simulated Body Fluid
The ability of apatite to form on the scaffold surface was evaluated
by in vitro bioactivity. For this test, the materials were immersed
in SBF with ion concentrations nearly equal to those of human
blood plasma. The test was performed by incubating the scaffolds
in SBF for 1, 3, or 7 days at 37 °C with steady agitation. SBF solu-
tion was prepared according to the published protocol of Kokubo
et al.[15] Briefly, NaCl, NaHCO3, KCl, KPO4.3H2O, MgCl2.6H2O,
HCl, CaCl2, Na2SO4, and TRIS were dissolved in ion-exchanged,
distilled water. The final pH was adjusted to 7.40 using HCl
(1 n). The solution was prepared always fresh and immediately
before use. Scaffolds were immersed into 10 mL SBF solution,
ensuring that all the material was fully covered. Plain SBF solu-
tion (i.e., without scaffolds) was used as a control for each obser-
vation time. After 1, 3, and 7 days, both the SBF solutions and
scaffolds were collected and analyzed.
2.3.1. Analysis of SBF Solutions Recovered after Scaffolds
Incubation: pH and Inductively Coupled Plasma Optical Emission
Spectroscopy
pH measurements were performed on all solutions recovered.
Furthermore, Ca and P concentrations were determined using in-
ductively coupled plasma optical emission spectroscopy (JY2000-
2, HORIBA Jobin Yvon, Kyoto, Japan). The solutions were filtered
using a 0.22 µm filter and diluted (1:10) in 1% nitric acid. All the
treated solutions were stored at −20 °C until further use. Plain
SBF solution was used as a control.
2.3.2. Analysis of the Scaffolds Harvested after SBF Incubation:
XRD, SEM-EDS, FTIR, and µCT
Scaffolds collected from the SBF solution were rinsed thoroughly
with ultra-pure water and allowed to dry overnight in a desicca-
tor. Subsequently, the scaffolds were analyzed by thin-film XRD,
SEM-EDS, FTIR, and µCT to evaluate chemical changes and
the mineral deposits on the scaffold surface, among other rele-
vant features. XRD, SEM-EDS, and FTIR were used as described
above. For µCT, no iodine staining was performed on the scaf-
folds recovered from SBF. Instead, scaffolds were scanned with-
out any previous treatment. NRecon (Version 1.6.9.18, Bruker)
software was used for reconstruction of the tomography data. The
different phases were distinguished using a CTAnalyser (Version
1.17.7.2, Bruker). Briefly, a multi-level Otsu method was used to
separate the greyscale value on the entire dataset into six distinct
phases. The grey scale value 25–85 was shown in white (chitosan-
collagen structure), the value 100–160 was shown in yellow (cal-
cium phosphate deposit), and the value 200–220 was shown in
red (HA deposit).
2.4. Cell Isolation and Seeding on the Scaffolds
The ethical committee of the University Hospital “Klinikum
rechts der Isar” at the Technical University of Munich, Germany
approved the described study. All procedures were performed in
accordance with the declaration of Helsinki in its latest amend-
ment. For all cellular experiments described hereafter, hAMSCs
were isolated and used. Fresh human fat tissue harvested from
abdominal fat of N = 3 patients was used. Patients provided in-
formed consent.
Cells were isolated following the previously described
protocol.[16] Briefly, harvested fat tissue was cut into small
pieces, placed into 50 mL falcon tubes to which sterile Dul-
becco’s phosphate-buffered saline without calcium or mag-
nesium (DPBS, Sigma Aldrich) was added. The mixture was
centrifuged at room temperature for 10 min without brakes
(450 g). The resulting fat layer was collected into a new 50 mL
falcon tube and washed 2–3 times with DPBS. Collagenase solu-
tion (0.8 mg mL−1 DPBS, collagenase type II, Biochrom GmbH,
Berlin, Germany) was added and digestion was performed for
30 min in a 37 °C water bath. The digestion reaction was stopped
by filling the tubes with pre-warmed cell culture medium
(Dulbecco’s Modified Eagle’s Medium—DMEM, high glucose,
Sigma Aldrich) that had been supplemented with 10% fetal calf
serum (Sigma Aldrich) and 1% penicillin/streptomycin (Sigma
Aldrich). The solution was centrifuged for 10 min at 600 g and
subsequently the pellet was resuspended in supplemented cell
culture medium and filtered through a 40 µm cell strainer (BD
Falcon, Franklin Lakes, NJ, USA). The resulting cell suspension
was transferred into cell culture flasks. The cell seeding density
was 3000 cells cm−2. Cells isolated from each individual donor
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were cultured independently. The cell culture medium was
changed on the first day after isolation and subsequently twice
weekly. For the cellular studies described in this paper, hAMSCs
were used in passages 2 and 3.[16]
For cell seeding on the scaffolds, hAMSCs from 3 different
donors were pooled immediately before seeding. Four different
concentrations of cells were used (i.e., 104, 105, 5 × 105, and
106 cells per scaffold). The cell suspension containing the dif-
ferent cell concentrations were prepared in 50 µL supplemented
DMEM. Sterile scaffolds were carefully placed into 48-well plates
and the 50 µL cell suspension was pipetted onto the scaffold.
Care was taken to distribute the cell suspension homogeneously
throughout the entire scaffold. Cell-seeded scaffolds were placed
into an incubator for 1 h at 37 °C under 5% CO2. Thereafter,
500 µL supplemented DMEM was carefully added. The con-
structs were cultivated for up to 35 days and media change was
performed twice weekly.
2.5. Evaluation of cell attachment, toxicity, and proliferation
2.5.1. Cell Attachment, Distribution, and Morphology: SEM-EDS
After 14, 21, and 35 days of hAMSCs culture on the scaffolds,
specimens were removed from the culture media, washed twice
with DPBS and fixed for SEM. Briefly, the constructs were fixed
for 30 min with 2.5% glutaraldehyde in a 0.1 m sodium cacodylate
buffer (pH 7.4, 2% sucrose). The fixed scaffolds were washed with
sodium cacodylate buffer and dehydrated in a series of ethanol of
a concentration from 30% up to 100%. Critical point drying was
achieved by immersion of the samples in hexamethyldisilazane
(HMDS) for 10 min. Treatment with HMDS was repeated three
times. Scaffolds were used uncoated for EDS analysis and sput-
ter coated for SEM following the same procedure as previously
described in the present study.
2.5.2. Cell Viability and Potential Toxicity of the Scaffolds: Lactate
Dehydrogenase and Calcein-AM/PI Staining
To evaluate the biocompatibility of the developed scaffolds, cell
viability was evaluated at 3, 7, and 14 days after seeding. In
addition, the effect of the different cell concentrations used was
considered. For the assay, the concentration of LDH, a marker for
cell death, was evaluated in the supernatants collected after each
observation time. Fluitest LDH-L Kit (Analyticon Biotechnologies
AG, Lichtenfels, Germany) was used following the manufac-
turer’s instructions. All experiments were performed in triplicate
and were normalized to a standard curve. Furthermore, live-dead
staining was performed after 21 and 35 days of cell culture on the
scaffolds. Here, harvested scaffolds were washed carefully with
DPBS and subsequently incubated in 500 µL staining solution
(2µm calcein-AM (Sigma Aldrich) and 1.5µm propidium iodide
(Sigma Aldrich)). Following incubation at 37 °C for 20 min, the
cell morphology and distribution were evaluated in each layer
by confocal microscopy using an Fluoview FV10i microscope
(Olympus, Tokyo, Japan). Moreover, cell infiltration through the
entire scaffold was evaluated after 35 days of cell culture. For this,
cell-seeded scaffolds were horizontally sectioned, from top to
bottom, to obtain 5 individual pieces. Each piece was stained with
Calcein-AM/PI and imaged using the confocal microscope. In
an attempt to quantify cell morphology, ImageJ v1.53f (National
Institutes of Health, MD, USA) was used. Confocal microscopy
images corresponding to each zone of the scaffold after 21 days
of cell culture were converted to grey-scale, 8 bits images. Next,
a fixed threshold (min. 70 and max. 255) was introduced and a
binary image was created. The particle analysis tool from ImageJ
was used. Events smaller than 20 µm as well as cell clusters
were excluded from the analyzed population. Over 200 cells were
analyzed for each scaffold zone. Shape descriptor parameters
such as circularity, roundness, and aspect ratio (A/R) were
considered. Cells featuring values of circularity and roundness
between 0.7 and 1 were considered as round. Three independent
scientists performed the analysis and results were averaged.
2.5.3. Cell Proliferation: DNA Quantification
The ability of hAMSCs to proliferate on the scaffolds was assayed
by quantifying the DNA content after different observation times.
Therefore, cell seeded scaffolds were cultured for 3, 7, and 14
days. At each observation time, the samples were washed using
DPBS and digested using 500 µL papain solution (0.1 mg mL−1,
Sigma Aldrich) per scaffold. Digestion was performed overnight
at 65 °C. Subsequently, the solution was stored at −80 °C. Quan-
tification of DNA content was performed using the Quant-iT
PicoGreen dsDNA Assay Kit (Invitrogen) following the manufac-
turer’s instructions. Briefly, 70 µL digested cell solution and 70 µL
Quant-iT PicoGreen dsDNA working solution were pipetted into
a 96-well plate. The plate was incubated for 5 min at 37 °C in
the dark. The fluorescence was quantified at an emission wave-
length of 520 nm and an excitation wavelength of 485 nm using
a FLUOstar Omega photometer (BMG labtech, Ortenberg, Ger-
many). All experiments were performed in triplicate. DNA con-
centrations were calculated using a standard curve.
2.6. Evaluation of gene expression and cell differentiation
2.6.1. Alkaline Phosphatase Activity
Alkaline phosphatase (ALP) activity was determined after 3, 14,
and 21 days of culture. ALP substrate solution was prepared with
4-nitrophenyl phosphate (pNPP, Sigma Aldrich). In the presence
of ALP, pNPP substrate will be converted to an equal amount of
yellow-colored 4-nitrophenol (pNP). For the assay, the scaffolds
were washed twice with DPBS and incubated with ALP substrate
solution for 30 min at 37 °C. Following incubation, 100 µL of
the solution was transferred to a 96-well plate and the absorption
was determined at 405 nm in the FLUOstar Omega photometer.
All experiments were performed in triplicate. pNP concentrations
were calculated from a standard curve. ALP activity was reported
as a function of the pNP concentration found in each sample.
2.6.2. Expression of Apoptosis, Proliferation, Osteogenic, and
Chondrogenic Genes: Quantitative Real-Time PCR
Cell-seeded scaffolds were used to evaluate the expression of
apoptosis, proliferation, osteogenic, and chondrogenic markers.
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For apoptosis, the apoptosis regulator BCL2 and CASP3 were
evaluated. For proliferation, MCM5 and CCND1 were analyzed.
In the case of osteogenic differentiation, the expression of
COL1A1, COL3A1, BGLAP (osteocalcin), SPP1 (osteopontin),
and RUNX2 were evaluated. While for chondrogenesis, SOX9,
COL2A1, COL10A1, and ACAN markers were analyzed. In the
case of differentiation markers, the scaffolds were carefully sec-
tioned to analyze the gene expression in the bone and cartilage
layers independently. Thereby, only the upper (OCP-rich, bone
zone) or lower (cartilage zone) layer of the scaffold was used for
RNA isolation and further processing. Gene expression was per-
formed by quantitative real-time PCR. In brief, cell-seeded con-
structs were harvested using Tri Reagent (Sigma Aldrich) at 1,
3, 7, 14, and 21 days after culture. Subsequently, 100 µL chlo-
roform was added and the samples were incubated on ice for
10 min. Following centrifugation (14 000 g for 10 min at 4 °C),
the clear phase was transferred into tubes containing 250 µL iso-
propanol. Following another incubation step on ice, a pellet was
obtained by centrifugation (14 000 g for 10 min at 4 °C). Wash-
ing was performed with 70% ethanol and the final pellet was
resuspended in 30 µL ultra-pure, DNase- and RNase-free, PCR
grade water. Measurement of the total RNA content was per-
formed using a Hellma TrayCell Eppendorf BioPhotometer (Ep-
pendorf AG, Hamburg, Germany). The cDNA transcription was
performed using the First Strand cDNA Synthesis Kit (Thermo
Fisher, Waltham, MA, USA) following the manufacturer’s in-
structions. A Mastercycler nexus (Eppendorf AG) was used for
the synthesis of cDNA. Following transcription, all samples were
diluted with PCR grade water to a concentration of 10 ng µL−1.
Quantitative real-time PCR was performed using Sso Fast Eva-
Green Super Mix (Bio-Rad Laboratories Inc., Hercules, CA, USA)
in a Bio-Rad CFX96 thermal cycler (Bio-Rad Laboratories Inc.).
cDNA (30 ng) was used in a total reaction volume of 20 µL. Re-
sults were reported as fold expression normalized to the used
housekeeper (i.e., tubulin beta class I: TUBB). Therefore, theΔCT
method using a reference gene was used.
2.6.3. Matrix Deposition on the Scaffolds: Histology
Histology examination was performed at 21 and 35 days after cell
culture on the scaffolds. The cell-seeded constructs were washed
twice with DPBS and fixed with 3.7% paraformaldehyde. De-
hydration was performed using gradually increasing concentra-
tions of ethanol. Thereafter, specimens were embedded in paraf-
fin and sectioned in 7 µm slices. The rehydration process was
performed using Roti-Histol (Carl Roth GmbH, Karlsruhe, Ger-
many) and immersion in 100%, 95%, and 70% ethanol. Hema-
toxylin and eosin (H&E) staining was used to obtain an overview
of the cells populating the scaffolds. Briefly, specimens were
stained by 10 min immersion in hemalaun followed by a rins-
ing step in running tap water. The sections were immersed for
5 min in eosin solution and dehydrated using 70%, 95%, and
100% ethanol and Roti-Histol. SafO staining was used to de-
tect cartilage-specific ECM. For SafO, sections were treated with
hematoxylin QS solution for 5 min, washed in running tap water,
and subsequently rinsed rapidly with acid ethanol. Counterstain-
ing was performed by immersing the sections for 5 min in 0.05%
fast green solution. Subsequently, the sections were rinsed with
a 1% acetic acid solution and stained in 0.1% SafO solution by
immersion for 5 min. The dehydration process was performed
following the same procedure already described for H&E. Dried
specimens were mounted and imaged with a light microscope
(BZ9000 Biorevo, Keyence, Osaka, Japan). A general scan of the
entire sections was obtained using the software packages BZ-II
Viewer and BZ-II Analyzer (Keyence, Osaka, Japan). All images
were taken under the same exposure time and white balance was
regularly applied.
2.7. Statistical Analysis
Statistical analysis was performed using GraphPad prism version
5.00 (GraphPad Software, San Diego, CA, USA). Data are shown
as mean value ± standard deviation. For multiple group compar-
ison, either one-way or two-way analysis of variance (ANOVA)
followed by Tukey’s test was applied. Multiple t-test corrected by
Holm–Sidak was used to analyze the pH data as well as the Ca
and P concentrations. All experiments were performed at least in
triplicate (technical replicates = 3). p values are reported follow-
ing the GraphPad style (i.e., four digits after the decimal point).
A probability of p ≤ 0.05 was considered to be significant.
3. Results
3.1. Composite, Multilayered Scaffold with Smooth
Bone-to-Cartilage Interface Mimics the Osteochondral Structure
with Relevant Elements Present at the Bone Layer
Single unit scaffolds were obtained made of a chitosan-collagen-
OCP composite (Figure 2A,B). Throughout the entire length, the
chitosan-collagen composition as well as the presence of OCP
varied. Thereby, a graded scaffold was obtained. The scaffolds
were fabricated in such fashion that all present zones appeared
subsequently after each other in the same single 3D. Thus, the
specific tissue layers were not glued, stitched, or assembled to
one another post-fabrication. Macroscopic images (Figure 2A) il-
lustrate the fabricated scaffolds. A porous structure was observed
throughout the entire scaffold length. The scaffolds consisted of
three layers, that is, a bone layer, an interface, and a cartilage
layer (Figure 2A). Macro- and microscopically, a distinction be-
tween the two main layers present in the scaffold was possible.
Analysis of the scaffold surface topography (Figure 2A) showed
a slightly rougher surface at the bone and interface regions com-
pared to the cartilage region. This observation was supported by
morphology analysis using scanning electron microscopy (SEM,
Figure 2C). An SEM image obtained at lower magnification al-
lowed the observation of the entire scaffold structure (Figure 2C,
centered image). In this image, the transition between the differ-
ent areas of the scaffold could be observed. Moreover, the gradi-
ent in mineral content, from the bony toward the cartilage layer,
was also evidenced by the presence of shiny OCP particles. The
OCP-rich region was characterized by an irregular pore distribu-
tion, whereas the interface and cartilage layer were dominated
by aligned pores with a smoother surface (Figure 2C, left and
right images). The incorporation of OCP showed an even distri-
bution in the entire bony layer. The incorporation of OCP crys-
tals, solely into the bony layer, was confirmed by energy disper-
sive spectroscopy (EDS, Figure 2D). In the image, the presence
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Figure 2. Morphological and elemental characterization of obtained chitosan-collagen-octacalcium phosphate scaffolds. A) Digital light microscopy
images showing the different zones in the multilayered scaffold. The layers of the scaffold corresponding to the bone, interface, and cartilage regions are
indicated by colored boxes added to the images. Higher magnifications of the different zones are shown. The left panel shows the surface roughness of
each zone of the scaffolds. B) Macroscopic image showing the general appearance of the scaffolds. C) Scanning electron microscopy images illustrating
the microstructure and morphological features of the obtained scaffolds. The central panel shows the entire scaffold. Detailed, higher magnifications
images are depicted in the right and left panels for the cartilage and bone zones, respectively. D) Element mapping at the scaffolds’ surface by means
of energy dispersive spectroscopy. Starting at the left upper image, images shown correspond to: SEM, C (turquoise), P (green), Ca (red), O (pink), and
superposition of all elements.
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Figure 3. Microstructure, pore size, and wall thickness of obtained chitosan-collagen-octacalcium phosphate (OCP) scaffolds. A) 3D 𝜇CT reconstruc-
tion showing the cartilage (Scale bar = 250 µm) and bony layers (OCP particles in red, Scale bar = 100 µm) and B) 𝜇CT image of the different zones
of the scaffold. The layers of the scaffold corresponding to the bone (green), interface (orange), and cartilage (blue) regions are indicated by colored
boxes added to the images. The colors match the graphical representations for wall thickness and pore size distribution in each zone of the scaffold.
C) Wall thickness and D) pore size distribution for each area of the scaffold. The pore size distribution range (µm) was divided in quarters that rep-
resent four different pore size thresholds. The quarters are indicated with different grey color shadows. Provided values indicate the % of pores that
falls inside each size distribution threshold. Additionally, larger pores (i.e., >300 µm) are indicated inside a red box for each scaffold zone. For de-
termination of both wall thickness and pore size distribution, three independent regions of interest (ROI) representing each zone were selected (i.e.,
ROI (1) = cartilage, ROI (2) = interface, and ROI (3) = bone). N = 4 scaffolds were used for analysis. Data are shown as mean value ± standard
deviation.
of the elements C (turquoise), P (green), Ca (red), and O (pink)
could be clearly observed for the entire scaffold. P and Ca were
only detected in the zone corresponding to the bone, whereas C
and O displayed a homogenous distribution throughout the en-
tire scaffold length.
Micro-computed tomography (µCT) 3D reconstruction re-
vealed detailed information of the scaffold’s microstructure
(Figure 3A). A highly porous structure was confirmed for the
entire scaffold. Open and interconnected porosity characterized
the scaffolds in all zones. Sagittal and axial slices generated by
the µCT reconstruction (Figure 3B) indicated a rather unidirec-
tional porosity, with a fibril-like structure in the cartilage layer.
An irregular porosity, featuring round pores, was observed in the
bony layer. The incorporation of OCP into the bony layer was
also corroborated in the µCT analysis (Figure 3A, lower image,
OCP particles in red). The OCP particles, characterized by a high
attenuation in the µCT, were displayed as having a high den-
sity with a bright appearance and were thus highly visible in the
µCT scans. This clearly contrasted with the low density collagen-
chitosan composite material that constituted the overall scaffolds.
Despite the varying pore morphology in the different scaf-
fold layers, wall thickness (Figure 3C) and pore size distribution
(Figure 3D) remained similar throughout the scaffold structure.
Wall thickness was generally found to be <124 µm, with most of
the measurements in the range of 25–50 µm. Interestingly, wall
thickness increased toward the bony zone. In this region of the
scaffold, 4.59% of the measurements returned values between
124 and 223 µm. By contrast, only 0.30% of the measurements
in the cartilage layer showed wall thickness values <190 µm. Re-
garding pore size distribution, >90% of pores present in the en-
tire scaffold had a diameter <300 µm. Most of the pores were
between 75 and 240 µm, with a peak of ≈150 µm. Larger pores
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Figure 4. Mechanical properties of obtained chitosan-collagen-octacalcium phosphate (OCP) scaffolds. A) Evolution of the storage modulus (G′), loss
modulus (G″), and loss factor (tan 𝛿) with increasing frequency. Measurements were performed at 37 °C. Each curve corresponds to an average of three
different samples analyzed. B) Dependence of the dynamic (complex) shear modulus (G*) on f1/2 at 37 °C. Fitted line corresponds to the least-square
linear regression of the linear region. C) Average values for storage modulus (G′), loss modulus (G″), loss factor (tan 𝛿), loss angle (𝛿), and dynamic
(complex) shear modulus (G*) obtained at 1 Hz, with the corresponding standard deviation.
were found in the cartilage zone, where >8% of the pores were
>300 µm in contrast to only 1.95% of such dimensions in the
bony layer.
3.2. Multilayered Scaffolds Showed a Viscoelastic Behavior, with
Dynamic (Complex) Shear Modulus (G*) Markedly Influenced by
the Storage (Elastic) Modulus (G′)
The chitosan-collagen-OCP scaffolds showed a viscoelastic be-
havior characterized by storage modulus (G′) > loss modulus
(G″) for viscoelastic solids. G′, G″, and loss factor (tan 𝛿) in-
creased with frequency as shown in Figure 4A. This increase was
at first minimal and showed a steep increase for high frequen-
cies that are near to 10 Hz. G′ values were higher than G″ for the
studied frequency range of 0.1–10 Hz. The value of G′ was in the
range of 1500–4000 Pa while G″ was found to be <1000 Pa for the
mentioned frequency interval. Figure 4C shows values obtained
for G′ and G″ at a fixed frequency of 1 Hz. For that frequency, G′
was found to be 1710 ± 20 Pa while G″ was equal to 110 ± 10 Pa.
This indicates that the storage (elastic) modulus G′ is the major
contributor to the dynamic (complex) shear modulus (G*). This
also reveals that our scaffolds displayed a high degree of elastic-
ity. The loss factor tan 𝛿 was found to be equal to 0.064 (3.66°)
for the chitosan-collagen-OCP scaffolds. This value matches well
with reported ones for collagen-based materials. G* character-
izes the overall stiffness of materials, and it is considered one of
the most appropriate representations of their mechanical proper-
ties. G* values are dependent on the frequency. Thus, they were
determined by a frequency sweep test. Obtained results are de-
picted in Figure 4B, in which non-linear as well as linear behav-
iors could be identified. A non-linear relationship of G* with f½ is
found at low frequencies (i.e., <0.3 Hz), followed by a linear be-
havior that was lost at frequencies higher than 1 Hz. An equation
that describes the dependency of G* with frequency was obtained
for the chitosan-collagen-OCP scaffolds (Figure 4B, G* = 1556 +
163 f½).
3.3. Multilayered Scaffolds were Bioactive with Surface Deposits
Rich in Calcium and Phosphorus
Fourier-transformed infrared spectroscopy (FTIR) spectra ob-
tained for the raw materials and the chitosan-collagen-OCP com-
posite can be found in the Figure S1, Supporting Information.
The main bands on the spectra were assigned (Figure S1D, Sup-
porting Information) and the presence of the single materials was
confirmed in the composition of the blend.
Bioactive materials are expected to form an apatite-like layer
on their surface as a result of their incubation in SBF solution.
FTIR and X-Ray Diffraction (XRD) were performed to character-
ize the chemical and crystalline structures of the scaffold surface
deposits after SBF incubation. FTIR spectra obtained for the dif-
ferent scaffold layers are presented in Figure 5 (A: bone and B:
cartilage). The bands located at ≈1500–1650 cm−1 could be as-
signed to the amide I (vibration of valence of C=O) and amide
II (dubbing of N–H) bands. Those chemical groups are present
in the peptide bonds of collagen and in the acetyl groups of chi-
tosan. The band located at 1057 cm−1 was attributed to the sym-
metric stretching vibration of the PO4
3− group of OCP and HA,
while the band at ≈600 cm−1 corresponded to P–O bending vibra-
tions in PO4
3−. A well-defined peak, corresponding to the phos-
phate group, was clearly identified in the bony section of the scaf-
folds. With increasing incubation time in SBF, the intensity of
this band notably increased. This was generally not observed in
the cartilage layer of the scaffolds independently of the incuba-
tion time assayed. Noteworthy is the high intensity band at day 1,
which was more likely related to a possible interference from the
bony layer. XRD patterns are presented in Figure 5C. The peaks
with the highest intensities have been identified with an asterisk
(*) and can be observed in 2𝜃 at 26°, 32°, and 40° and a broad
peak around 50°. Several of the shown diffraction peaks could be
assigned to an apatite-like phase according to the Joint Commit-
tee on Power Diffraction Standards ASTM JCPDS 9-432. By in-
creasing the incubation time in SBF, the intensities of the apatite
peaks increased and the single peaks became better defined.
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Figure 5. Bioactivity of the chitosan-collagen-octacalcium phosphate (OCP) scaffolds. FTIR spectroscopy showing the chemical composition of the
scaffolds before and after immersion in simulated body fluid (SBF). Spectra obtained for A) bony and B) cartilage layers. C) X-ray diffraction spectra
showing the crystalline structure of the scaffolds before and after immersion in SBF. Relevant peaks have been identified in FTIR and XRD spectra with
an asterisk (*). D) Scanning electron microscopy images of the scaffolds at 1, 3, and 7 days after SBF incubation. E) Corresponding EDS elemental
analysis performed for each independent zone of the scaffolds before and after SBF incubation. The different incubation times analyzed (i.e., 1, 3, and 7
days) are depicted in the figure. F) pH of the solutions collected after scaffolds incubation in SBF. Obtained p values are indicated by ***p ≤ 0.0003. G)
Ca and P concentrations in the solutions collected after scaffolds incubation in SBF as determined by ICP spectroscopy. Obtained p values are indicated
by *p ≤ 0.0243, **p ≤ 0.0038, and ***p = 0.0001. H) Mineral deposit on the scaffolds after SBF incubation as determined by 𝜇CT. Material composition
have been color coded for better visualization; chitosan-collagen in white, OCP and formed HA in orange to red coloration. Experiments were performed
in triplicate (technical replicates = 3). Data are shown as mean value ± standard deviation. Multiple t-test corrected using Holm–Sidak for multiple
comparisons was used for statistical analysis of pH data as well as Ca and P determinations.
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SEM-EDS was also performed to characterize the bioactiv-
ity (Figure 5D). Because of the distinctive appearance of apatite
grains and layers, SEM has been widely used—sometimes as the
sole technique—to estimate apatite layer formation. In our study,
a significant change in the topography of the scaffold surface was
observed after incubation in SBF. Globular aggregates were ob-
served that completely covered the surface of the scaffolds at day 3
post-incubation. Following 7 days in SBF, a compact cauliflower-
like coating was observed (Figure 5D, right panel). The presence
of Ca, P, C, and O was detected by EDS analysis (Figure 5E). At
days 1 and 3 post-incubation, higher wt% of Ca and P were iden-
tified in the bony layer of the scaffold. Unexpectedly, at day 7,
these elements were slightly higher in wt% in the cartilage zone.
The concentration of Ca and P in solution decreased over time
(determined by ICP, Figure 5G). This decrease correlated well
with a pH increase (Figure 5F) obtained at 1, 3, and 7 days post-
incubation.
Specimens collected after SBF incubation were also analyzed
by µCT (Figure 5H). In the reconstructed images, the chitosan-
collagen structure is shown in white color. The OCP particles
(incorporated in the bony layer) and the HA formed are shown
in orange-to-red colors. After 1 day of incubation in SBF, only
the OCP particles located in the bony zone of the scaffold were
visible. By increasing the incubation time, the number of or-
ange and red particles was elevated, indicating an increase in the
amount of HA deposited on the scaffold. These deposits were
mostly located in the bony area in agreement with the results
obtained by the SEM/EDS analysis. Following 1 week of incuba-
tion, the entire scaffold was covered with HA deposits. This also
matched the dense apatite-like layer recognized in the SEM for
the same observation time. Noteworthy is the occurrence of slight
shrinkage in the scaffolds after SBF incubation. This behavior
was noticeable mostly in the cartilage part of the multilayered
scaffolds.
3.4. Viable Human Adipose-Derived Mesenchymal Stem Cells
Proliferated on the Multilayered Scaffolds
Cells were seeded on the scaffolds using a range of cell densi-
ties of 104–106 cells per scaffold. Cell proliferation was dependent
on the cell number and culture time employed (Figure 6A). Re-
markably, only a cell density of 105 cells per scaffold displayed a
significant elevation of the cell proliferation with increased cul-
ture time (3 vs 14 days of culture: p = 0.0260 and 7 vs 14 days
of culture: p = 0.0065). For the lowest (104 cells per scaffold) and
highest (≥5 × 105 cells per scaffold) cell densities tested, no sig-
nificant differences were observed for cell proliferation between
3, 7, or 14 days after cell seeding (p ≥ 0.0658). This indicated a low
proliferative behavior of the cells under these culture conditions.
Furthermore, 105 cells per scaffold may be optimal for hAMSCs
to proliferate in the scaffolds under the culture conditions tested.
The toxicity related to the scaffold materials was evaluated for the
different cell densities used by quantifying the lactate dehydroge-
nase (LDH) activity released to the supernatant (Figure 6B). Inter-
estingly, the highest LDH quantities were detected for the highest
initial cell density, that is, 106 cells per scaffold. Even so, LDH lev-
els still significantly decreased with culture time (p < 0.0001). No-
ticeably, lower cell densities resulted in significantly lower LDH
production (104 vs 106 cells per scaffold showed p < 0.0001 for
days 3 and 7 after culture and p = 0.0051 for day 14). Here also,
LDH detection significantly decreased from day 3 to day 7 after
cell seeding (p ≤ 0.05 for all cell densities except for 106 cells per
scaffold) and remained low for the rest of the culture time. This
indicated that the cell toxicity observed for 106 cells per scaffold
was not related to the scaffold material but rather to the high cell
density used per scaffold area. Based on the overall results from
the cell proliferation and toxicity evaluations, a cell density of 105
cells per scaffold was used in subsequent experiments.
From the confocal images displayed in Figure 6C, a good cell
attachment and homogenous cell distribution were visible in
all layers of the scaffold. In particular, cells could be observed
that colonized the entire scaffold structure independently of the
tissue-specific zone. By means of a live/dead calcein-AM/PI stain-
ing, further insights on cell viability were obtained. All zones of
the scaffold were individually observed. At 21 days after seed-
ing, large areas of green stained cells were observed that indi-
cated a high number of viable cells in all zones of the scaffold.
Interestingly, a higher cell density was present at the cartilage
zone when compared to the bony and interface layers. Cells in
the cartilage area appeared rather elongated. The cellular orien-
tation was observed in the direction of the scaffold pores. In the
bony layer, the cells displayed a more roundish morphology. In
the interface region, a mixture of both morphologies was ob-
served. Cell morphology was analyzed using ImageJ and shape
descriptor parameters such as circularity and roundness were cal-
culated (Figure 6D). A value of 1 for both parameters indicates a
perfect mathematical circle. Only 5.14% of the cells in the car-
tilage area featured values of circularity and roundness between
0.7 and 1. Conversely, 18.7% of the cells in the bony part showed
values in the same range. In the interface zone, 10.6% of the
cells showed circularity and roundness >0.7 in accordance to the
microscopic observations. Dead cells were also identified in all
three zones of the scaffold (Figure 6C, cell nuclei stained red).
However, this was no longer observed at 35 days after seeding.
At this observation time, a negligible number of dead cells were
identified.
Further effects of the scaffolds on hAMSCs viability were an-
alyzed by qPCR of proliferation and apoptosis markers (Fig-
ure 6E). Both minichromosome maintenance complex compo-
nent 5 (MCM5) and cyclin D1 (CCND1) genes encode for pro-
teins relevant in cell proliferation. Indeed, the protein encoded
by MCM5 is involved in the initiation of DNA replication and is
thus active in the regulation of the cell cycle. Similarly, CCND1
expression directly alters cell cycle progression. Following 7 days
of hAMSCs culture on the scaffolds, a significant upregulation
was observed for MCM5 (p < 0.0001) and CCND1 (p < 0.0001).
This upregulation was more pronounced for CCND1 (24.9-fold
increased upregulation compared to MCM5). B-cell lymphoma
2 (BCL2) and caspase 3 (CASP3) were investigated as indicators
for possible apoptotic effects of the scaffolds on hAMSCs. BCL2, a
gene that encodes a protein blocking the apoptotic death of cells,
was significantly upregulated already at 3 days post-culture (p =
0.0013). Interestingly, also CASP3, which plays a key role in the
execution-phase of cell apoptosis, showed a significantly higher
expression at 7 days of culture (p < 0.0001).
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Figure 6. Biocompatibility of the chitosan-collagen-octacalcium phosphate scaffolds using hAMSCs. A) Cell proliferation and B) cell viability of hAMSCs
seeded at different densities for up to 14 days of culture on the scaffolds. Two-way ANOVA followed by a Tukey’s correction for multiple comparisons was
performed. Obtained p values are indicated as follows: DNA *p = 0.0260 and **p = 0.0065; LDH activity **p = 0.0013, ***p ≤ 0.0006, and ****p < 0.0001.
C) Calcein-AM/Propidium iodide live/dead staining performed in each specific zone of the scaffolds after 21 and 35 days of hAMSC culture (105 cells
per scaffold). Calcein AM stains live cells green, while Propidium iodide stains dead cells red. Scale bar = 200 µm. After 35 days of culture, cell-seeded
scaffolds were horizontally sectioned. Each piece (numbered from 1 to 5 in the scheme) was independently imaged in the confocal microscope. Thus,
cell colonization in the entire scaffold can be appreciated. Scale bar = 200 µm. D) ImageJ analysis of the cell morphology performed for each specific
zone of the scaffolds after 21 days of hAMSC culture. Circularity values of 1 indicate a perfect circle. Round objects also feature high roundness and
low aspect-ratio (A/R) values. Over 200 cells were analyzed in each part of the scaffold. Cells that displayed circularity and roundness values between
0.7 and 1 were considered round. This range has been indicated in the graphs using red, discontinued lines. E) Expression of proliferation (MCM5 and
CCND1) and apoptosis (BCL2 and CASP3) markers by hAMSCs seeded on the scaffolds (105 cells per scaffold) after different culture times. Results are
normalized to the housekeeper TUBB. One-way ANOVA followed by a Tukey’s correction for multiple comparisons was performed. Obtained p values
are indicated as **p = 0.0013 and ****p < 0.0001. Experiments were performed in triplicate (technical replicates = 3). Data are shown as mean value ±
standard deviation.
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Figure 7. hAMSCs adhesion and morphology after seeding on the chitosan-collagen-octacalcium phosphate scaffolds at A) 14 days, B) 21 days, and C)
35 days of cell culture. The three different panels represent different magnifications used to analyze the samples (i.e., ×30, ×500, and ×2500). From left
to right, the boxed area indicates where the magnification was taken that is shown in the next panel.
3.5. Human Adipose-Derived Mesenchymal Stem Cells
Colonized the Entire Scaffold Surface, Displayed Multiple
Intercellular Connections and Produced Extracellular Matrix
SEM was applied to evaluate cell distribution and morphology
after hAMSCs culture on the scaffolds (Figure 7A–C). Interest-
ingly, pores on the scaffold surface appeared to be occupied at
21 and 35 days after culture (overview image taken at ×30, left
panel). At these observation times, more cellular material and
ECM were visible (Figure 7B,C, image ×500, center panel) that
may be occluding the scaffold pores. Good cell distribution and
attachment were observed at the scaffold surface. Cells were vis-
ible in the bony and cartilage layers of the scaffold. Additionally,
the cell density appeared to increase after longer culture peri-
ods. Interestingly, at the cartilage area, the scaffold surface had
a smooth and flat appearance in which cells were well attached
(Figure 7B, ×500, center panel). The morphology of the cells was
elongated and abundant cell-cell contact could be observed (Fig-
ure 7B, ×500 center panel and ×2500 right panel). At the bony
layer, cells were attached surrounded by mineral deposits on a
rougher surface (Figure 7A,C, ×500 center panel). Ample min-
eral deposition could be observed for the bony layer in images
taken at ×2500 (Figure 7A,C, ×2500 right panel). After 35 days of
culture on the scaffolds, cells covered the entire surface, display-
ing multiple intercellular connections and ECM production.
3.6. Ionic Composition of the Extracellular Matrix at the Scaffold
Bony and Cartilage Layers
SEM-EDS results are depicted for scaffolds without cells
(Figure 8A, control scaffolds) and for scaffolds with cells after
14, 21, and 35 days of culture (Figure 8B–D). The bone and carti-
lage layers were analyzed independently. On the control scaffolds,
OCP incorporation in the bony region was detectable, while no
Ca or P was measurable in the cartilage region (Figure 8A). With
increasing cell culture time, a higher percentage of Ca and of P
was detectable for both the bone and cartilage areas. This was par-
ticularly noticeable for the bone layer of the scaffolds, featuring
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Figure 8. EDS elemental analysis performed for each independent zone of the scaffolds after hAMSCs culture. A) Results before cell culture. Results
after B) 14 days, C) 21 days, and D) 35 days of cell culture. Values of wt% are tabulated for C, O, Ca, and P for each experimental condition analyzed.
the highest Ca and P percentages (21.9% and 9.3%, respectively,
Figure 8D, left EDS spectrum).
3.7. Specific Differentiation of Human Adipose-Derived
Mesenchymal Stem Cells Occurred That was Associated with the
Scaffold Zones
All analyzed osteogenic markers showed an increased expression
in hAMSCs seeded on the bony layer of the scaffolds (Figure 9A).
Upregulation was observed for bone gamma-carboxyglutamate
protein (BGLAP, p= 0.0022) at 14 days after culture. For the same
time of observation, an increase on expression was detected for
RUNX family transcription factor 2 (RUNX2) although not signif-
icant (p = 0.0520). Both, BGLAP and RUNX2 were upregulated
at 21 days after culture (p < 0.05). Interestingly, collagen type
I 𝛼1 chain (COL1A1) and collagen type III 𝛼1 chain (COL3A1)
expression reached a maximum level at 14 days after culture.
Remarkably, secreted phosphoprotein 1 (SPP1) displayed a very
early expression at 3 days after culture on the scaffolds. The SPP1
expression levels further increased at 21 days after culture (p =
0.0190). ALP activity was also evaluated as an indicator for os-
teogenesis. ALP increased over culture time, although this incre-
ment was not statistically significant (Figure 9B, p > 0.05).
SRY-box transcription factor 9 (SOX9) expression was evalu-
ated to gain an insight in early chondrogenesis. Cells seeded on
the cartilage layer of the scaffolds displayed a significant upreg-
ulation of SOX9 after 14 days of culture (Figure 9C, p = 0.0005).
Later, at 21 days after culture, SOX9 expression significantly de-
creased (p = 0.0022), such that a peak was observed at 14 days.
Other markers, including collagen type II 𝛼1 chain (COL2A1)
and collagen type X 𝛼1 chain, showed expression up to 21 days
of hAMSCs culture on the cartilage layer of the scaffolds. Inter-
estingly, aggrecan (ACAN) displayed same levels of expression
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Figure 9. Spatial-specific gene expression and matrix deposition of hAMSCs after seeding on the chitosan-collagen-octacalcium phosphate scaffolds.
A) Expression of osteogenic markers (COL1A1, BGLAP, SPP1, and RUNX2) and matrix-related fibrillar COL3A1 were assayed by qRT-PCR after 3, 14,
and 21 days of hAMSC culture on the scaffolds. Results are normalized to the housekeeper TUBB. Obtained p values are indicated as *p ≤ 0.0418, **p ≤
0.0034, ***p ≤ 0.0007, and ****p < 0.0001. B) ALP activity as determined by colorimetric assay (p > 0.05). C) Expression of chondrogenic markers (SOX9,
COL2A1, COL10A1, and ACAN) assayed by qRT-PCR after 3, 14, and 21 days of cell culture, was normalized to the housekeeper TUBB. Results showed
statistical significance only for SOX9 (**p = 0.0022 and ***p = 0.0005). D) H&E and SafO staining of the entire scaffold after extended culture time
(i.e., 21 and 35 days of cell culture). Scale bar = 1000 µm. Dashed squares represent the area of the scaffolds where higher magnification images were
taken. Scale bar = 200 µm. All data are shown as mean value ± standard deviation. One-way ANOVA followed by a Tukey’s correction was performed
for multiple comparisons. Experiments were performed in triplicate (technical replicates = 3).
during the entire cell culture period. Safranin O (SafO) staining
after 35 days of hAMSCs culture on the scaffolds revealed a more
intense staining pattern when compared to earlier culture times
(Figure 9D).
4. Discussion
Functional repair of soft-to-hard tissue transitions remains chal-
lenging in orthopedic surgery. Clinical options feature limita-
tions, while current research strives to develop better solutions
that are rapidly translatable into patient care. In this respect, the
use of tissue-engineered scaffolds may be attractive for the treat-
ment of osteochondral lesions. Generally, one of the problems
when designing 3D scaffolds for tissue interfaces is that two dif-
ferent tissue types and the interface must be considered. Fre-
quently, different materials are glued together to recreate individ-
ual layers that mimic the different tissue characteristics.[5b] Such
approach clearly presents the limitation of poor integration be-
tween the two layers.[17] In fact, most previous studies present
two-layer scaffolds for osteochondral repair[18] that are obtained
by combining individual parts for each specific tissue. Poor inte-
gration has been reported as one of the limitations of this com-
binatorial fabrication strategy.[5b,17] Gao et al. and Chen et al. in-
troduced the use of fibrin glue to combine a bony and a cartilage
scaffold.[19] Other studies recommend suturing or press fitting
both layers.[20] These studies relied on the eventual formation of
ECM produced by the cells initially seeded on the scaffold lay-
ers to achieve biological integration. This may be a cumbersome,
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hard-to-translate approach lacking proper integration of the bony
and cartilage layers, in which the interface is barely considered.
In the present study, we developed a single scaffold unit that was
fabricated using biomaterial gradients. Our aim was to mimic
the structure of articular cartilage and subchondral bone by tai-
loring the composite material and microstructure. Our scaffold
design agrees with that reported by Levingstone et al.[8c,21] The au-
thors developed a multi-layered collagen-based scaffold that was
obtained by an iterative layering fabrication. They also considered
a cartilage, interface, and bony layer. Our work and that of Lev-
ingstone et al. demonstrate that good integration and mechani-
cal stability can be obtained by a layering fabrication approach. In
fact, similarly to Levingstone et al., our scaffold did not show any
delamination of the different layers during mechanical character-
ization. Obtained values for G′, G″, 𝛿, and G* are within the range
of collagen materials[22] and other biopolymers often used for
cartilage regeneration (e.g., alginate gels[23] and hyaluronan[24]).
Nevertheless, mechanical properties of our scaffolds were found
to be lower than those reported for native articular cartilage.[22b]
This is a common problem in scaffolds for cartilage engineer-
ing. One possibility will be incorporating proteoglycan-rich ma-
terials to the composite. They feature 𝛿 of 70° and may increase
the typical collagen materials’ 𝛿 of 3.6° to a more cartilage-like of
≈15°.[22b] Inorganic compounds have been used with similar aim.
The approach followed by Parisi et al. of introducing four differ-
ent gradient zones using HA showed improved mechanics.[25]
We followed these ideas in that we used a biopolymer-ceramic
composite rather than collagen alone. It may be also interest-
ing to crosslink the matrix during fabrication. However, while
crosslinking is known to increase matrix stiffness,[22a] it has been
well-documented that scaffolds with minimal crosslinking and
low initial stiffness result in beneficial stimulation on the syn-
thesis of cartilage-related molecules by cells.[22a,26] Crosslinking
has been also associated to toxicity.[22a]
In addition to good integration and mechanical stability,
osteochondral scaffolds should feature adequate porosity and
biocompatibility.[5b] Remarkably, porosity has been reported to
highly impact cellular behavior in osteochondral constructs.[27]
Our scaffolds were porous, with the pore size ranging mostly
from 75 to 240 µm throughout the entire length of the scaffold.
Microscopy analysis showed highly interconnected pores. This
may have led to the good cellular distribution and extensive
cell-to-cell connections observed from 14 days onward. Larger
pores were obtained in the cartilage layer of our scaffolds. Pan
et al. studied the effect of scaffold porosity on osteochondral
repair in vivo.[27] The authors concluded that the scaffold with
greater porosity and a larger pore size of the cartilage layer
(i.e., 92% porosity, pores 200–300 µm) exhibited the best repair
efficacy. Our results are in agreement with the results of Pan
et al.[27] Larger pores and greater porosity at the cartilage zone of
our scaffolds supported good osteochondral features in vitro. To
warrant biocompatibility, our scaffolds were designed to feature
a material gradient including chitosan, collagen, and OCP. Both,
collagen and chitosan are natural-origin biopolymers, highly bio-
compatible that present bone and cartilage ECM-like features.[28]
The chitosan-collagen-OCP scaffolds developed in our study were
biocompatible, promoting good cell adhesion and proliferation.
Our results are in agreement with Yan et al., who also demon-
strated good cytocompatibility of MSCs with chitosan-collagen
porous scaffolds.[29] In vivo, their scaffolds supported differen-
tiation of seeded MSCs toward the desired pathway. For bone,
to confer additional bone-like features to chitosan and chitosan-
blends, diverse biomimetic coating approaches have been inves-
tigated. Tuzlakoglu et al.[30] and Leonor et al.[31] reported that
bioglass spraying and calcium silicate immersion, respectively,
enhanced biomineralization of resulting chitosan biomaterials.
Levingstone et al.[8c,21] and Parisi et al.[25] used HA in the bony
layer of their collagen-based osteochondral scaffolds. In our
study, we incorporated OCP particles into the chitosan-collagen
blend to further improve bioactivity and biomineralization at the
bone layer of the scaffolds. OCP features superior in vitro and
in vivo osteogenic properties compared to HA and other inor-
ganic materials.[32] In vitro, it has been demonstrated that OCP
promoted osteoblast differentiation and cell conversion to late
osteocytes, while HA and beta-tricalcium phosphate did not.[33]
OCP can be highly resorbed by osteoclasts.[34] In fact, OCP can
be remodeled by new bone in vivo in contrast to HA. The latter
is known to be present for years at the defect site.[32,35] The in
vivo superiority of OCP was first described in a pioneer study by
Suzuki et al.[36] The authors reported superior osteoconductive
properties of OCP when compared to four different inorganic
materials, that is di-calcium phosphate, amorphous calcium
phosphate, Ca-deficient HA, and HA. The OCP material had the
earliest time of new bone tissue deposition (i.e., 1 week post-
implantation). In our study, by incorporating OCP in a gradual
manner, bioactivity and mineral deposition increased at the bony
end of the scaffolds. Interestingly, cell morphology also appeared
to be impacted by the presence of OCP particles in the scaffolds.
Expression of osteogenic genes, for example, RUNX2, COL1A1,
BGLAP, and SPP1, also increased over time in the OCP-rich layer
of the scaffolds. Similar osteogenic features have been reported
by other authors for OCP biomaterials. Anada et al. observed an
enhanced expression of COL1A1, ALPL, and SP7 in mouse bone
marrow stromal cells upon stimulation on OCP coatings.[37]
Kouketsu et al. reported an increased level of RUNX2, COL1A1,
BGLAP, and SPP1 in vivo at 4 weeks post-OCP implantation.[38]
Also relevant is the gene expression of cells at the osteochondral
interface. Negligible COL2A1 and ACAN expression combined
with high collagen type X 𝛼1 chain (COL10A1) expression have
been reported for the interface area.[39] Our results on gene ex-
pression coincide with these reports. Our osteochondral scaffold
facilitated simultaneous expression of markers for differentiated
and hypertrophic chondrocyte-like cells.
Limitations of our study are the lack of in vivo validation of
the results observed in vitro. These experiments should be per-
formed as part of the preclinical evaluation of this new bioma-
terial. Further composite optimization may be needed in order
to achieve mechanic properties closer to that of the native tis-
sue. Furthermore, an extended in-depth investigation should be
conducted to characterize chondrogenesis at the cartilage layer.
Importantly, no growth factor or other biologic was used in
our study. The chitosan-collagen-OCP scaffolds displayed bio-
compatibility and specific tissue regeneration potential based
solely on microstructural features and biomaterial combinations
and gradients. This is advantageous for clinical applications.
Growth factor-loaded scaffolds may pose high costs and present
considerable side effects for the patients. However, it might
be that such biologic is nevertheless needed to achieve robust
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chondrogenesis. Furthermore, the chitosan-collagen-OCP scaf-
folds are produced as soft and flexible sponges of large size
(>5 cm; sponge dimensions depend on the mold used during
fabrication). The sponges are easy to sterilize and manipulate.
Therefore, this offers the surgeon the possibility to cut out the
exact size needed with a scalpel directly prior to implantation
into the patient defect. No cost-intensive or complex patient-
individual production would be required.
5. Conclusion
Collectively, our results demonstrate the feasibility of the multi-
phasic chitosan-collagen-OCP composite scaffold for osteochon-
dral regeneration. We demonstrated the incorporation of OCP
at the top of the bony layer, forming a diminishing gradient
toward the cartilage zone, to be a successful approach for os-
teogenic induction in the bony layer. The porosity and pore size
together with the higher concentration of collagen in the cartilage
layer resulted stimulative for chondrogenesis. Based on this, we
conclude that multiphasic scaffolds designed as a continuous,
single unit using composites of materials and gradients thereof
may be promising for osteochondral repair. Relevant aspects to
consider are selecting materials that mimic the natural ECM of
bone and cartilage and following an adequate scaffold design that
allows the development of a mechanically and chemically stable
scaffold, where the tissue interface is also considered. Moreover,
specific pore size for each tissue zone is highly important and
this should be carefully considered.
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